

Giovanni Grignani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/246539/publications.pdf>

Version: 2024-02-01

151
papers

9,135
citations

50276
46
h-index

46799
89
g-index

155
all docs

155
docs citations

155
times ranked

8364
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Soft tissue and visceral sarcomas: ESMOâ€“EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018, 29, iv51-iv67. | 1.2 | 641 |
| 2 | Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. <i>Lancet, The</i> , 2016, 387, 1629-1637. | 13.7 | 610 |
| 3 | Gastrointestinal stromal tumours: ESMOâ€“EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018, 29, iv68-iv78. | 1.2 | 413 |
| 4 | Soft tissue and visceral sarcomas: ESMOâ€“EURACANâ€“GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-upâ†. <i>Annals of Oncology</i> , 2021, 32, 1348-1365. | 1.2 | 381 |
| 5 | Bone sarcomas: ESMOâ€“PaedCanâ€“EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018, 29, iv79-iv95. | 1.2 | 380 |
| 6 | Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-ST5 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. <i>Lancet Oncology, The</i> , 2017, 18, 812-822. | 10.7 | 370 |
| 7 | A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. <i>Annals of Oncology</i> , 2012, 23, 508-516. | 1.2 | 296 |
| 8 | Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial. <i>Lancet Oncology, The</i> , 2015, 16, 98-107. | 10.7 | 270 |
| 9 | Phase II Study of Imatinib in Advanced Chordoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 914-920. | 1.6 | 230 |
| 10 | Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial. <i>Lancet Oncology, The</i> , 2017, 18, 1089-1103. | 10.7 | 214 |
| 11 | Gastrointestinal stromal tumours: ESMOâ€“EURACANâ€“GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2022, 33, 20-33. | 1.2 | 213 |
| 12 | Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways. <i>Molecular Cancer</i> , 2009, 8, 118. | 19.2 | 159 |
| 13 | Bone sarcomas: ESMOâ€“EURACANâ€“GENTURISâ€“ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2021, 32, 1520-1536. | 1.2 | 150 |
| 14 | Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplasmâ€“a position paper from the Italian and the French Sarcoma Group. <i>Annals of Oncology</i> , 2014, 25, 578-583. | 1.2 | 149 |
| 15 | Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis. <i>Acta OncolÃ³gica</i> , 2017, 56, 88-92. | 1.8 | 146 |
| 16 | Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups. <i>Journal of Clinical Oncology</i> , 2020, 38, 2178-2186. | 1.6 | 145 |
| 17 | Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine. <i>Journal of Clinical Oncology</i> , 2017, 35, 3433-3439. | 1.6 | 126 |
| 18 | The role of surgery in the multimodal treatment of primary gastric non-Hodgkin's lymphomas a report of 76 cases and review of the literature. <i>Cancer</i> , 1990, 65, 2528-2536. | 4.1 | 120 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial. <i>Lancet Oncology</i> , 2019, 20, 134-144. | 10.7 | 97 |
| 20 | The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 Upregulation in Osteosarcoma Preclinical Models. <i>Clinical Cancer Research</i> , 2013, 19, 2117-2131. | 7.0 | 96 |
| 21 | Treatment of Extraspinal Painful Bone Metastases with Percutaneous Cementoplasty: A Prospective Study of 50 Patients. <i>CardioVascular and Interventional Radiology</i> , 2008, 31, 1165-1173. | 2.0 | 93 |
| 22 | Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): long-term follow-up of a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group. <i>Annals of Oncology</i> , 2016, 27, 2283-2288. | 1.2 | 90 |
| 23 | Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. <i>Cancer</i> , 2020, 126, 2637-2647. | 4.1 | 86 |
| 24 | Tumor response assessment by modified Choi criteria in localized high-risk soft tissue sarcoma treated with chemotherapy. <i>Cancer</i> , 2012, 118, 5857-5866. | 4.1 | 85 |
| 25 | Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial. , 2020, 8, e001561. | | 85 |
| 26 | EURO-B.O.S.S.: A European study on chemotherapy in bone-sarcoma patients aged over 40: Outcome in primary high-grade osteosarcoma. <i>Tumori</i> , 2018, 104, 30-36. | 1.1 | 84 |
| 27 | Involvement of chemokine receptor 4/stromal cell-derived factor 1 system during osteosarcoma tumor progression. <i>Clinical Cancer Research</i> , 2005, 11, 490-7. | 7.0 | 83 |
| 28 | Effective Activity of Cytokine-Induced Killer Cells against Autologous Metastatic Melanoma Including Cells with Stemness Features. <i>Clinical Cancer Research</i> , 2013, 19, 4347-4358. | 7.0 | 81 |
| 29 | Primary metastatic Ewing's family tumors: results of the Italian Sarcoma Group and Scandinavian Sarcoma Group ISG/SSC IV Study including myeloablative chemotherapy and total-lung irradiation. <i>Annals of Oncology</i> , 2012, 23, 2970-2976. | 1.2 | 80 |
| 30 | Preoperative chemo-radiation therapy for localised retroperitoneal sarcoma: A phase II study from the Italian Sarcoma Group. <i>European Journal of Cancer</i> , 2014, 50, 784-792. | 2.8 | 80 |
| 31 | Predicting Survival in Patients Undergoing Resection for Locally Recurrent Retroperitoneal Sarcoma: A Study and Novel Nomogram from TARPSWG. <i>Clinical Cancer Research</i> , 2019, 25, 2664-2671. | 7.0 | 80 |
| 32 | Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone. <i>BMC Cancer</i> , 2016, 16, 280. | 2.6 | 71 |
| 33 | Quality of surgery and neoadjuvant combined therapy in the ISG-GEIS trial on soft tissue sarcomas of limbs and trunk wall. <i>Annals of Oncology</i> , 2013, 24, 817-823. | 1.2 | 69 |
| 34 | Cytokine-Induced Killer Cells Eradicate Bone and Soft-Tissue Sarcomas. <i>Cancer Research</i> , 2014, 74, 119-129. | 0.9 | 67 |
| 35 | Extraskeletal osteosarcoma: A European Musculoskeletal Oncology Society study on 266 patients. <i>European Journal of Cancer</i> , 2017, 74, 9-16. | 2.8 | 67 |
| 36 | Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts. <i>ESMO Open</i> , 2021, 6, 100170. | 4.5 | 65 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 37 | A prognostic index for multiple myeloma. <i>British Journal of Cancer</i> , 1996, 73, 1101-1107. | 6.4 | 64 |
| 38 | Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma. <i>JAMA Oncology</i> , 2018, 4, e180219. | 7.1 | 63 |
| 39 | Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group. <i>Lancet Oncology</i> , The, 2018, 19, 1360-1371. | 10.7 | 61 |
| 40 | Pazopanib for treatment of advanced extraskeletal myxoid chondrosarcoma: a multicentre, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1252-1262. | 10.7 | 57 |
| 41 | Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access program. , 2020, 8, e000313. | | 54 |
| 42 | Genome-Wide Analysis Identifies MEN1 and MAX Mutations and a Neuroendocrine-Like Molecular Heterogeneity in Quadruple WT GIST. <i>Molecular Cancer Research</i> , 2017, 15, 553-562. | 3.4 | 53 |
| 43 | Pazopanib for treatment of typical solitary fibrous tumours: a multicentre, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 456-466. | 10.7 | 51 |
| 44 | Phase 2 trial of two courses of cyclophosphamide and etoposide for relapsed high-risk osteosarcoma patients. <i>Cancer</i> , 2009, 115, 2980-2987. | 4.1 | 50 |
| 45 | Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour. <i>European Journal of Cancer</i> , 2014, 50, 3021-3028. | 2.8 | 50 |
| 46 | Post-Transplant Cyclophosphamide and Tacrolimus-Mycophenolate Mofetil Combination Prevents Graft-versus-Host Disease in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 459-466. | 2.0 | 50 |
| 47 | Next generation immune-checkpoints for cancer therapy. <i>Journal of Thoracic Disease</i> , 2018, 10, S1581-S1601. | 1.4 | 50 |
| 48 | PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models. <i>Molecular Cancer</i> , 2017, 16, 86. | 19.2 | 49 |
| 49 | High-risk soft tissue sarcomas treated with perioperative chemotherapy: Improving prognostic classification in a randomised clinical trial. <i>European Journal of Cancer</i> , 2018, 93, 28-36. | 2.8 | 49 |
| 50 | Percutaneous Vertebroplasty in Multiple Myeloma: Prospective Long-Term Follow-Up in 106 Consecutive Patients. <i>CardioVascular and Interventional Radiology</i> , 2012, 35, 139-145. | 2.0 | 47 |
| 51 | Allogeneic nonmyeloablative hematopoietic cell transplantation in metastatic colon cancer: tumor-specific T cells directed to a tumor-associated antigen are generated in vivo during GVHD. <i>Blood</i> , 2006, 107, 3795-3803. | 1.4 | 46 |
| 52 | Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: A Sarculator-based risk stratification analysis of the ISGSTS 1001 randomized trial. <i>Cancer</i> , 2022, 128, 85-93. | 4.1 | 46 |
| 53 | A phase 2 trial of imatinib mesylate in patients with recurrent nonresectable chondrosarcomas expressing platelet-derived growth factor receptor-1 or -2. <i>Cancer</i> , 2011, 117, 826-831. | 4.1 | 42 |
| 54 | Irinotecan and temozolomide in recurrent Ewing sarcoma: an analysis in 51 adult and pediatric patients. <i>Acta Oncologica</i> , 2018, 57, 958-964. | 1.8 | 41 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | High dose chemotherapy with autologous hematopoietic stem cell support for solid tumors other than breast cancer in adults. <i>Annals of Oncology</i> , 2006, 17, 1479-1488. | 1.2 | 39 |
| 56 | Complete Resolution of Life-Threatening Bleomycin-Induced Pneumonitis After Treatment With Imatinib Mesylate in a Patient With Hodgkin's Lymphoma: Hope for Severe Chemotherapy-Induced Toxicity?. <i>Journal of Clinical Oncology</i> , 2011, 29, e691-e693. | 1.6 | 38 |
| 57 | CD44v6 as innovative sarcoma target for CAR-redirected CIK cells. <i>Oncolimmunology</i> , 2018, 7, e1423167. | 4.6 | 38 |
| 58 | Next-Generation Sequencing Approaches for the Identification of Pathognomonic Fusion Transcripts in Sarcomas: The Experience of the Italian ACC Sarcoma Working Group. <i>Frontiers in Oncology</i> , 2020, 10, 489. | 2.8 | 38 |
| 59 | Cytokine-Induced Killer Cells Kill Chemo-surviving Melanoma Cancer Stem Cells. <i>Clinical Cancer Research</i> , 2017, 23, 2277-2288. | 7.0 | 34 |
| 60 | Cabozantinib Affects Osteosarcoma Growth Through A Direct Effect On Tumor Cells and Modifications In Bone Microenvironment. <i>Scientific Reports</i> , 2018, 8, 4177. | 3.3 | 34 |
| 61 | Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib. <i>British Journal of Cancer</i> , 2017, 117, 1278-1285. | 6.4 | 33 |
| 62 | Assessment of Safety and Efficacy of Combined Trabectedin and Low-Dose Radiotherapy for Patients With Metastatic Soft-Tissue Sarcomas. <i>JAMA Oncology</i> , 2020, 6, 535. | 7.1 | 33 |
| 63 | Clinical Use of AMD3100 to Mobilize CD34+ Cells in Patients Affected by Non-Hodgkin's Lymphoma or Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2005, 23, 3871-3872. | 1.6 | 30 |
| 64 | Defining the role of neoadjuvant systemic therapy in high-risk retroperitoneal sarcoma: A multi-institutional study from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group. <i>Cancer</i> , 2021, 127, 729-738. | 4.1 | 30 |
| 65 | Treatment patterns and clinical outcomes with pazopanib in patients with advanced soft tissue sarcomas in a compassionate use setting: results of the SPIRE study. <i>Acta Oncologica</i> , 2017, 56, 1769-1775. | 1.8 | 29 |
| 66 | The sacral chordoma margin. <i>European Journal of Surgical Oncology</i> , 2020, 46, 1415-1422. | 1.0 | 29 |
| 67 | Impact of a risk-based follow-up in patients affected by gastrointestinal stromal tumour. <i>European Journal of Cancer</i> , 2017, 78, 122-132. | 2.8 | 28 |
| 68 | Pancreaticoduodenectomy in the surgical management of primary retroperitoneal sarcoma. <i>European Journal of Surgical Oncology</i> , 2018, 44, 810-815. | 1.0 | 28 |
| 69 | Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591879462. | 3.2 | 27 |
| 70 | The Activity of Chemotherapy in Inflammatory Myofibroblastic Tumors: A Multicenter, European Retrospective Case Series Analysis. <i>Oncologist</i> , 2020, 25, e1777-e1784. | 3.7 | 27 |
| 71 | Postoperative Morbidity After Resection of Recurrent Retroperitoneal Sarcoma: A Report from the Transatlantic Australasian RPS Working Group (TARPSWG). <i>Annals of Surgical Oncology</i> , 2021, 28, 2705-2714. | 1.5 | 26 |
| 72 | 153Samarium-EDTMP administration followed by hematopoietic stem cell support for bone metastases in osteosarcoma patients. <i>Annals of Oncology</i> , 2012, 23, 1899-1905. | 1.2 | 25 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 73 | Complete remission of paraneoplastic vanishing bile duct syndrome after the successful treatment of Hodgkin's lymphoma: a case report and review of the literature. BMC Research Notes, 2014, 7, 529. | 1.4 | 24 |
| 74 | The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma. BMC Cancer, 2015, 15, 374. | 2.6 | 24 |
| 75 | CSPG4-Specific CAR-CTL Lymphocytes as a Novel Therapy for the Treatment of Multiple Soft-Tissue Sarcoma Histotypes. Clinical Cancer Research, 2020, 26, 6321-6334. | 7.0 | 24 |
| 76 | Anticoagulation for Central Venous Catheters in Patients with Cancer. New England Journal of Medicine, 2014, 371, 1362-1363. | 27.0 | 23 |
| 77 | Systemic therapies in advanced epithelioid haemangioendothelioma: A retrospective international case series from the World Sarcoma Network and a review of literature. Cancer Medicine, 2021, 10, 2645-2659. | 2.8 | 23 |
| 78 | MOPP/EBV/CAD hybrid chemotherapy with or without limited radiotherapy in advanced or unfavorably presenting Hodgkin's disease: a report from the Italian Lymphoma Study Group.. Journal of Clinical Oncology, 1993, 11, 712-719. | 1.6 | 22 |
| 79 | Gain of FGF4 is a frequent event in KIT/PDGFR α /SDH/RAS Δ WT GIST. Genes Chromosomes and Cancer, 2019, 58, 636-642. | 2.8 | 22 |
| 80 | Evaluation of the use and efficacy of (neo)adjuvant chemotherapy in angiosarcoma: a multicentre study. ESMO Open, 2020, 5, e000787. | 4.5 | 22 |
| 81 | High Dose Ifosfamide in Relapsed and Unresectable High-Grade Osteosarcoma Patients: A Retrospective Series. Cells, 2020, 9, 2389. | 4.1 | 22 |
| 82 | Randomized, open-label, multicenter, phase III study of eribulin versus dacarbazine in patients (pts) with leiomyosarcoma (LMS) and adipocytic sarcoma (ADI).. Journal of Clinical Oncology, 2015, 33, LBA10502-LBA10502. | 1.6 | 22 |
| 83 | An Acute Hepatitis Resembling Autoimmune Hepatitis Occurring During Imatinib Therapy in a Gastrointestinal Stromal Tumor Patient. American Journal of Clinical Oncology: Cancer Clinical Trials, 2009, 32, 640-641. | 1.3 | 21 |
| 84 | Ex Vivo Allogeneic Stimulation Significantly Improves Expansion of Cytokine-Induced Killer Cells Without Increasing Their Alloreactivity Across HLA Barriers. Journal of Immunotherapy, 2012, 35, 579-586. | 2.4 | 21 |
| 85 | Patterns of recurrence and survival probability after second recurrence of retroperitoneal sarcoma: A study from TARPSWG. Cancer, 2020, 126, 4917-4925. | 4.1 | 21 |
| 86 | Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice. Therapeutic Advances in Medical Oncology, 2017, 9, 731-739. | 3.2 | 20 |
| 87 | Cytokine Induced Killer cells are effective against sarcoma cancer stem cells spared by chemotherapy and target therapy.. Oncoimmunology, 2018, 7, e1465161. | 4.6 | 20 |
| 88 | Assessment of morphological CT imaging features for the prediction of risk stratification, mutations, and prognosis of gastrointestinal stromal tumors. European Radiology, 2021, 31, 8554-8564. | 4.5 | 20 |
| 89 | Pharmacokinetics, safety, and activity of trabectedin as first-line treatment in elderly patients who are affected by advanced sarcoma and are unfit to receive standard chemotherapy: A phase 2 study (TR1US) Tj ETQq1 1.0.784314rgBT /Ov | 4.0 | 19 |
| 90 | Analysis of Differentiation Changes and Outcomes at Time of First Recurrence of Retroperitoneal Liposarcoma by Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG). Annals of Surgical Oncology, 2021, 28, 7854-7863. | 1.5 | 19 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 91 | Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity. Journal of Translational Medicine, 2016, 14, 119. | 4.4 | 18 |
| 92 | Soft tissue sarcoma in Italy: From epidemiological data to clinical networking to improve patient care and outcomes. Cancer Epidemiology, 2019, 59, 258-264. | 1.9 | 18 |
| 93 | NKTR-214 + nivolumab in first-line advanced/metastatic urothelial carcinoma (mUC): Updated results from PIVOT-02.. Journal of Clinical Oncology, 2019, 37, 388-388. | 1.6 | 18 |
| 94 | Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study. Clinical Cancer Research, 2022, 28, 1672-1679. | 7.0 | 18 |
| 95 | Olaratumab: PDGFR- α inhibition as a novel tool in the treatment of advanced soft tissue sarcomas. Critical Reviews in Oncology/Hematology, 2017, 118, 1-6. | 4.4 | 16 |
| 96 | Targeted Deep Sequencing Uncovers Cryptic KIT Mutations in KIT/PDGFR α /SDH/RAS-P Wild-Type GIST. Frontiers in Oncology, 2020, 10, 504. | 2.8 | 16 |
| 97 | A phase II randomised (calibrated design) study on the activity of the single-agent trabectedin in metastatic or locally relapsed uterine leiomyosarcoma. British Journal of Cancer, 2018, 119, 565-571. | 6.4 | 15 |
| 98 | Pazopanib and Trametinib as a Synergistic Strategy against Osteosarcoma: Preclinical Activity and Molecular Insights. Cancers, 2020, 12, 1519. | 3.7 | 15 |
| 99 | Trabectedin for Patients with Advanced Soft Tissue Sarcoma: A Non-Interventional, Retrospective, Multicenter Study of the Italian Sarcoma Group. Cancers, 2021, 13, 1053. | 3.7 | 15 |
| 100 | Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial. Journal of Clinical Oncology, 2022, 40, 2479-2490. | 1.6 | 15 |
| 101 | In vivo characterisation of soft tissue tumours by 1.5-T proton MR spectroscopy. European Radiology, 2012, 22, 1131-1139. | 4.5 | 14 |
| 102 | Morbidity and Outcomes After Distal Pancreatectomy for Primary Retroperitoneal Sarcoma: An Analysis by the Trans-Atlantic Australasian Retroperitoneal Sarcoma Working Group. Annals of Surgical Oncology, 2021, 28, 6882-6889. | 1.5 | 14 |
| 103 | IMMUNOSARC: a collaborative Spanish (GEIS) and Italian (ISG) sarcoma groups phase I/II trial of sunitinib and nivolumab in advanced soft tissue and bone sarcoma: Results from the phase II part, bone sarcoma cohort.. Journal of Clinical Oncology, 2020, 38, 11522-11522. | 1.6 | 14 |
| 104 | Painful Pathologic Fracture of the Humerus: Percutaneous Osteoplasty With Bone Marrow Nails Under Hybrid Computed Tomography and Fluoroscopic Guidance. Journal of Vascular and Interventional Radiology, 2011, 22, 1031-1034. | 0.5 | 13 |
| 105 | Alpha-fetoprotein elevation in NUT midline carcinoma: a case report. BMC Cancer, 2017, 17, 266. | 2.6 | 13 |
| 106 | Management of Locally Recurrent Retroperitoneal Sarcoma in the Adult: An Updated Consensus Approach from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group. Annals of Surgical Oncology, 2022, 29, 7335-7348. | 1.5 | 13 |
| 107 | Adoptive immunotherapy against sarcomas. Expert Opinion on Biological Therapy, 2015, 15, 517-528. | 3.1 | 11 |
| 108 | Confirmed Activity and Tolerability of Weekly Paclitaxel in the Treatment of Advanced Angiosarcoma. Sarcoma, 2016, 2016, 1-7. | 1.3 | 11 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | Delving into PARP inhibition from bench to bedside and back. , 2020, 206, 107446. | | 11 |
| 110 | Trabectedin clinical cases: use according to indication in diverse clinical scenarios. Future Oncology, 2015, 11, 15-24. | 2.4 | 10 |
| 111 | Post-Transplant Cyclophosphamide and Tacrolimusâ€”Mycophenolate Mofetil Combination Governs GVHD and Immunosuppression Need, Reducing Late Toxicities in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors. Journal of Clinical Medicine, 2021, 10, 1173. | 2.4 | 10 |
| 112 | Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma. Future Oncology, 2021, 17, 2923-2939. | 2.4 | 10 |
| 113 | Standard versus personalized schedule of regorafenib in metastatic gastrointestinal stromal tumors: a retrospective, multicenter, real-world study. ESMO Open, 2021, 6, 100222. | 4.5 | 10 |
| 114 | Telomere loss in Philadelphia-negative hematopoiesis after successful treatment of chronic myeloid leukemia: Evidence for premature aging of the myeloid compartment. Mechanisms of Ageing and Development, 2012, 133, 479-488. | 4.6 | 9 |
| 115 | Analytic and Dynamic Secretary Profile of Patient-Derived Cytokine-Induced Killer Cells. Molecular Medicine, 2017, 23, 235-246. | 4.4 | 9 |
| 116 | Validation process of Toronto Extremity Salvage Score in Italian: A quality of life measure for patients with extremity bone and soft tissue tumors. Journal of Surgical Oncology, 2020, 121, 630-637. | 1.7 | 9 |
| 117 | Progressive necrotic myelopathy as a paraneoplastic syndrome: report of a case and some pathogenetic considerations. Journal of Internal Medicine, 1992, 231, 81-85. | 6.0 | 8 |
| 118 | Allogeneic Hemopoietic Stem Cell Transplantation in Solid Tumors. Transplantation Proceedings, 2005, 37, 2664-2666. | 0.6 | 8 |
| 119 | Successful treatment of gemcitabine-induced acute interstitial pneumonia with imatinib mesylate: a case report. BMC Cancer, 2016, 16, 793. | 2.6 | 8 |
| 120 | Avelumab expanded access program in metastatic Merkel cell carcinoma: Efficacy and safety findings from patients in Europe and the Middle East. International Journal of Cancer, 2021, 149, 1926-1934. | 5.1 | 8 |
| 121 | Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study. , 2022, 10, e004419. | | 8 |
| 122 | Night sweats in Hodgkin's disease A manifestation of preceding minor febrile pulses. Cancer, 1990, 65, 2074-2077. | 4.1 | 7 |
| 123 | Response to melphalan in up-front investigational window therapy for patients with metastatic Ewingâ€™s family tumours. European Journal of Cancer, 2007, 43, 885-890. | 2.8 | 7 |
| 124 | A plea to overcome the concept of â€œstagingâ€• and related inadequacy in multiple myeloma. European Journal of Haematology, 1991, 46, 177-181. | 2.2 | 7 |
| 125 | EphA2 Expression in Bone Sarcomas: Bioinformatic Analyses and Preclinical Characterization in Patient-Derived Models of Osteosarcoma, Ewingâ€™s Sarcoma and Chondrosarcoma. Cells, 2021, 10, 2893. | 4.1 | 7 |
| 126 | <sc>CINSARC</sc> in highâ€™risk soft tissue sarcoma patients treated with neoadjuvant chemotherapy: Results from the <sc>ISGâ€™CTS</sc> 1001 study. Cancer Medicine, 2023, 12, 1350-1357. | 2.8 | 7 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 127 | Gingival metastasis of a radiotherapy-induced breast angiosarcoma. <i>Anti-Cancer Drugs</i> , 2012, 23, 1112-1117. | 1.4 | 6 |
| 128 | Prognostic role of PD-L1 and immune-related gene expression profiles in giant cell tumors of bone. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1905-1916. | 4.2 | 6 |
| 129 | Prolonged Disease Stability With Trabectedin in a Heavily Pretreated Elderly Patient With Metastatic Leiomyosarcoma of the Thigh and Renal Failure: A Case Report and Review of the Literature. <i>Oncology Research</i> , 2012, 20, 483-490. | 1.5 | 5 |
| 130 | Preventing Venous Thromboembolism in Patients with Cancer. <i>New England Journal of Medicine</i> , 2019, 380, 2180-2181. | 27.0 | 5 |
| 131 | Avelumab treatment in Italian patients with metastatic Merkel cell carcinoma: experience from an expanded access program. <i>Journal of Translational Medicine</i> , 2021, 19, 70. | 4.4 | 5 |
| 132 | Front-Line Window Therapy with Temozolomide and Irinotecan in Patients with Primary Disseminated Multifocal Ewing Sarcoma: Results of the ISG/AIEOP EW-2 Study. <i>Cancers</i> , 2021, 13, 3046. | 3.7 | 5 |
| 133 | Weekly cisplatin with or without imatinib in advanced chordoma: A retrospective case-series analysis from the Italian Rare Cancers Network. <i>Cancer</i> , 2022, 128, 1439-1448. | 4.1 | 5 |
| 134 | Case Report: Clinical Experience With Avelumab in Patients With Metastatic Merkel Cell Carcinoma and Brain Metastases Treated in Europe. <i>Frontiers in Oncology</i> , 2021, 11, 672021. | 2.8 | 4 |
| 135 | SDHA Germline Variants in Adult Patients With SDHA-Mutant Gastrointestinal Stromal Tumor. <i>Frontiers in Oncology</i> , 2021, 11, 778461. | 2.8 | 4 |
| 136 | Systemic treatment in advanced phyllodes tumor of the breast: a multi-institutional European retrospective case-series analyses. <i>Breast Cancer Research and Treatment</i> , 2022, 192, 603-610. | 2.5 | 4 |
| 137 | Activity of cytokine-induced killer cells against bone and soft tissue sarcoma. <i>Oncoimmunology</i> , 2014, 3, e28269. | 4.6 | 3 |
| 138 | Primary mesenteric sarcomas: Collaborative experience from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG). <i>Journal of Surgical Oncology</i> , 2021, 123, 1057-1066. | 1.7 | 3 |
| 139 | Eribulin-based treatment in patients affected by sarcomas: a case series. <i>Future Oncology</i> , 2020, 16, 1-3. | 2.4 | 3 |
| 140 | Nationwide multidisciplinary consensus on the clinical management of Merkel cell carcinoma: a Delphi panel. , 2022, 10, e004742. | | 3 |
| 141 | Response to eribulin in a patient with metastatic uterine leiomyosarcoma: a case report. <i>Future Oncology</i> , 2020, 16, 15-19. | 2.4 | 2 |
| 142 | Predictive Value of MRP-1 in Localized High-Risk Soft Tissue Sarcomas: A Translational Research Associated to ISG-STG 1001 Randomized Phase III Trial. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 2539-2552. | 4.1 | 2 |
| 143 | Maintenance therapy with oral cyclophosphamide plus celecoxib in patients with metastatic Ewing sarcoma: Results of the Italian Sarcoma Group/AIEOP EW-2 study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10517-10517. | 1.6 | 2 |
| 144 | Front-line window therapy with cisplatin in patients with primary disseminated Ewing sarcoma: A study by the Associazione Italiana di Ematologia ed Oncologia Pediatrica and Italian Sarcoma Group. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26650. | 1.5 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 145 | Whole Lung Irradiation after High-Dose Busulfan/Melphalan in Ewing Sarcoma with Lung Metastases: An Italian Sarcoma Group and Associazione Italiana Ematologia Oncologia Pediatrica Joint Study. Cancers, 2021, 13, 2789. | 3.7 | 1 |
| 146 | Tumor progression in osteosarcoma (OS): Role of the chemokine receptor CXCR4 and of its ligand stromal-cell derived factor 1 (SDF-1). Journal of Clinical Oncology, 2004, 22, 9021-9021. | 1.6 | 1 |
| 147 | Gastrointestinal Stromal Tumors. , 2012, , 41-60. | | 1 |
| 148 | Immunological and Genetic Biomarkers of Sarcomas. , 2019, , 591-608. | | 0 |
| 149 | Endoscopic submucosal dissection for chronically bleeding gastric metastasis from undifferentiated liposarcoma. Digestive and Liver Disease, 2020, 52, 588. | 0.9 | 0 |
| 150 | Medical Therapy in Retroperitoneal Sarcomas. Updates in Surgery Series, 2019, , 133-141. | 0.1 | 0 |
| 151 | PARP1 Inhibitor and Trabectedin Combination Does Not Increase Tumor Mutational Burden in Advanced Sarcomas—A Preclinical and Translational Study. Cancers, 2021, 13, 6295. | 3.7 | 0 |